The development of drugs for the treatment of rare diseases is difficult, as is the development of safe methods of diagnosis. Although the number of patients suffering from rare diseases is relatively large, the estimated 8,000 different rare…
In late January the Sars-Cov-2 pandemic officially arrived and started spreading across Germany. Since then – like in almost every other country globally - every new day feels completely new, uncertain and presents previously unknown challenges,…
At the beginning of 2019, the British foundation Wellcome Trust opened an office in Berlin, thus expanding its activities to Germany. The first project funded by the foundation in Germany is a translation partnership with the Berlin Institute of…
The pharmaceutical company Bayer wants to help turn Berlin into a biotech hub like Boston. This is possible, says head of research Stefan Oelrich in an interview with the Tagesspiegel.
Myelo Therapeutics GmbH, a clinical-stage pharmaceutical company focused on developing therapies for cancer supportive care and medical countermeasures (MCM), announced that it has been awarded a 3-year development contract valued at up to $6…
Repeats of individual building blocks within proteins are the cause of many hereditary diseases, but how such repeats actually cause disease is still largely unknown. Researchers in Berlin investigated how repeat elongations lead to the disease…
NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), provided a corporate update on its measures in response to the potential impact of…
Opening a fund to help to ensure vital parts for COVID-19 related projects are manufactured.
Debiopharm, a Swiss-based biopharmaceutical company announced having entered into a worldwide, exclusive license & research agreement with 3B Pharmaceuticals (3BP), a German biotechnology firm, to further the development of their radioligand program,…
“In the beginning, no one could really imagine how such complex systems like ‘AI symptom checkers’ could be benchmarked, but now this topic group is showing to be actually cracking this nut.” Developing an internationally recognized standardized…
